Logo image
CTA1-DD is an effective adjuvant for targeting anti-chlamydial immunity to the murine genital mucosa
Journal article   Open access   Peer reviewed

CTA1-DD is an effective adjuvant for targeting anti-chlamydial immunity to the murine genital mucosa

Kelly A. Cunningham, Alison J. Carey, Nils Lycke, Peter Timms, Kenneth W. Beagley and Sahlgrenska akademin
Journal of reproductive immunology, v 81(1), pp 34-38
2009
PMID: 19501917
url
https://eprints.qut.edu.au/30260/1/CTA1-DD_is_an_effective_adjuvant_for_targeting_anti-chlamydial_immunity_to_the_murine_genital_mucosa.pdfView

Abstract

Chlamydia CTA1-DD Mucosal adjuvant
Chlamydia trachomatis is a significant human pathogen with potentially severe disease sequelae in the genital tract, including infertility. A successful vaccine will need to effectively target immunity to the genital mucosa. Intranasal immunisation with cholera toxin (CT) can target immunity to the genital tract, but has the potential to cause neurological side effects. CTA1-DD is a non-toxic potent mucosal adjuvant which combines the enzymatic properties of CT, with a B cell targeting moiety. Here, we demonstrate that intranasal immunisation with CTA1-DD and chlamydial Major Outer Membrane Protein (MOMP) results in the induction of neutralising systemic and mucosal antibodies, and reduces the level of chlamydial shedding following intravaginal challenge with Chlamydia muridarum. Thus, CTA1-DD is an effective adjuvant for vaccine development against Chlamydia trachomatis, and possibly also a range of other genital pathogens.

Metrics

7 Record Views
36 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
International collaboration
Web of Science research areas
Immunology
Reproductive Biology
Logo image